Is Crinetics Pharmaceuticals, Inc. (CRNX) a Buy, Sell, or Hold?
NASDAQ : CRNX
Crinetics Pharmaceuticals, Inc.
$83.7181 USD
$0.09 (0.11%)
- Volume
- 1.06M
- Average Volume
- 3.69M
- Market Capitalization
- $8.86B
- P/E Ratio
- -16.29
- Dividend Yield
- 0.00%
- Price Target
- $85.00
- Year High
- $84.00
- Year Low
- $25.83
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $18.60
Company Overview
NASDAQ
R. Scott Struthers
Biotechnology
Healthcare
CRNX
594
US
USD
Liquidity Metrics
0.04
18.60
18.56
1.61
0.00
Sales & Valuation
$7.7M
490.38
6.81
-21.12
-4.03
Profitability
-$4.95
-$465.32M
-2747.18%
-2746.18%
-43.96%
-35.42%
P/E Metrics
-16.29
0.59
0.59
Analyst Price Target & Rating
$85.00
$85.00
$84.00
2/5
21 Analysts
-1.51%
Financial Health Scores
42.54
2/9
$1.25B
$1.4B
$120.68M
-$496.21M
Key Metrics (TTM)
$8.78B
486.19
-17.85
18.60
-43.96%
-40.83%
-5.70%
-4.74%
-17798 days
Company Executives
| Name | Title |
|---|---|
| Alan S. Krasner | Chief Endocrinologist |
| Tobin C. Schilke | Chief Financial Officer |
| Kea Lingo | Chief Information Officer |
| Kevin Capps | Head of Intellectual Property |
| Gayathri Diwakar | Head of Investor Relations |
| Natalie Badillo | Head of Corporate Communications |
| Adriana Cabre | Chief Human Resources Officer |
| Stephen F. Betz | Co-Founder & Chief Scientific Officer |
| Chris Robillard | Chief Business Officer |
| Garlan Adams | Chief Legal Officer & Corporate Secretary |
| R. Scott Struthers | Founder, President, Chief Executive Officer & Director |
Poll Results
No votes yet today — be the first to share your view!
About Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Stock
Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin receptor type 2 agonist. This compound has concluded its Phase III clinical trials for the treatment of acromegaly, and has also completed Phase II trials targeting carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). Furthermore, the company's pipeline includes CRN04777, an oral selective non-peptide somatostatin type 5 receptor agonist, which is currently undergoing Phase I clinical trials for congenital hyperinsulinism. Another inves ... tigational drug, CRN04894, an oral adrenocorticotrophic hormone antagonist, is in Phase I clinical trials for Cushing's disease and congenital adrenal hyperplasia. Crinetics Pharmaceuticals, Inc. was founded in 2008 and maintains its headquarters in San Diego, California.
Are CRNX, VEEE, NXTC, TCBK Obtaining Fair Deals for their Shareholders?
2026-07-21 14:51:00
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
2026-07-21 11:03:00
BALA CYNWYD, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no cost or financial obligation to you.
2026-07-21 07:37:00
MILWAUKEE, July 21, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating Crinetics (Nasdaq: CRNX) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Vertex.
2026-07-15 11:13:00
NEW YORK, July 15, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating
2026-07-15 11:13:00
NEW YORK, July 15, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde and Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report.
2026-07-14 10:31:00
BALA CYNWYD, Pa., July 14, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no cost or financial obligation to you.
Here's Why Vertex Was Willing to Pay a Premium of More Than 100% for Crinetics Pharmaceuticals
2026-07-14 08:00:00
Atumelnant is a promising treatment for congenital adrenal hyperplasia that could be a key part of Vertex's future. Management says it was "floored" by its results in clinical trials.
Does Vertex's Acquisition of Crinetics Pharmaceuticals Make the Stock a No-Brainer Buy?
2026-07-13 14:27:07
Vertex is buying Crinetics Pharmaceuticals for $10 billion. The acquisition could add up to $5 billion in revenue.
Frequently Asked Questions
-
What is the current Crinetics Pharmaceuticals, Inc. (CRNX) stock price?
-
Crinetics Pharmaceuticals, Inc.(NASDAQ:CRNX) stock price is $83.7181 in the last trading session. During the trading session, CRNX stock reached the peak price of $84 while $25.83 was the lowest point it dropped to. The percentage change in CRNX stock occurred in the recent session was 0.11% while the dollar amount for the price change in CRNX stock was $0.09.
-
CRNX's industry and sector of operation?
-
The NASDAQ listed CRNX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of CRNX?
-
Alan S. Krasner | Chief Endocrinologist
Tobin C. Schilke | Chief Financial Officer
Kea Lingo | Chief Information Officer
Kevin Capps | Head of Intellectual Property
Gayathri Diwakar | Head of Investor Relations -
How many employees does CRNX have?
-
Number of CRNX employees currently stands at 594. CRNX operates from 6055 Lusk Boulevard, San Diego, CA 92121, US.
-
Link for CRNX official website?
-
Official Website of CRNX is: https://www.crinetics.com
-
How do I contact CRNX?
-
CRNX could be contacted at phone #858 450 6464 and can also be accessed through its website. CRNX operates from 6055 Lusk Boulevard, San Diego, CA 92121, US.
-
How many shares of CRNX are traded daily?
-
The average number of CRNX shares traded daily for last 3 months was 3.69M.
-
What is the market cap of CRNX currently?
-
The market value of CRNX currently stands at $8.86B with its latest stock price at $83.7181